Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Blake, Stephen J., Stannard, Kimberley, Liu, Jing, Allen, Stacey, Yong, Michelle C.R., Mittal, Deepak, Aguilera, Amelia Roman, Miles, John J., Lutzky, Viviana P., de Andrade, Lucas Ferrari, Martinet, Ludovic, Colonna, Marco, Takeda, Kazuyoshi, Kühnel, Florian, Gurlevik, Engin, Bernhardt, Günter, Teng, Michele W.L., Smyth, Mark J.·2016·Cancer Discovery

Abstract

CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell activity, with Cd96−/− mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFNγ, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti–CTLA-4, anti–PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit−/− mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFNγ production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases. Significance: This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96–CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade. Cancer Discov; 6(4); 446–59. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 331

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0944

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 243

Metadata

Authors
Blake, S. J., Stannard, K., Liu, J., Allen, S., Yong, M. C. R., Mittal, D., Aguilera, A. R., Miles, J. J., Lutzky, V. P., de Andrade, L. F., Martinet, L., Colonna, M., Takeda, K., Kühnel, F., Gurlevik, E., Bernhardt, G., Teng, M. W. L., & Smyth, M. J.
Venue
Cancer Discovery
Published
2016-04-01
Volume
6
Issue
4
Pages
446-459
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2332535881
Cited by
243
References
11
FWCI
14.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. https://app.cochat.ai/papers/10.1158/2159-8290.cd-15-0944
The paper
Blake, S. J., Stannard, K., Liu, J., Allen, S., Yong, M. C. R., Mittal, D., Aguilera, A. R., Miles, J. J., Lutzky, V. P., de Andrade, L. F., Martinet, L., Colonna, M., Takeda, K., Kühnel, F., Gurlevik, E., Bernhardt, G., Teng, M. W. L., & Smyth, M. J. (2016). Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-15-0944

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.